Theravance Biopharma, Inc. Reports Third Quarter 2023 Financial Results and Provides Business Update

Q3 2023 YUPELRI® net sales, recognized by Viatris, increased 9% from Q3 2022, reaching an all-time high of $58.3 million1Progress made towards the achievement of non-GAAP profitability, with Q3...

Related Keywords

United States ,Denmark ,Copenhagen ,Køavn ,Ireland ,Dublin ,Erick Graham ,Ricke Winningham ,Richarda Graham ,Theravance Biopharma ,Burton Malkiel ,Us Department Of Justice ,Development At Theravance Biopharma ,Teva Pharmaceuticals United States Inc ,Mylan Ireland ,Company Annual Report On Form ,Symphony Health ,Development Rd Expenses ,Company Form ,National Institute Of Neurological Disorders ,International Congress ,Neurological Institute ,Teva Pharmaceuticals Inc ,Prnewswire Theravance Biopharma Inc ,Allergan ,International Symposium ,Alkermes ,While Viatris Inc ,Securities Exchange ,Movement Disorders Congress ,Theravance Biopharma Inc ,Chief Executive ,Autonomic Nervous System ,Net Loss ,Viatris Collaboration Revenue ,Royalty Pharma ,Financial Results ,Based Compensation ,Discontinued Operations ,Net Income ,Vice President ,Clinical Safety ,General Meeting ,Mylan Ireland Limited ,Settlement Agreement ,Teva Pharmaceuticals ,Teva Pharmaceuticals United States ,Hatch Waxman Act ,Orange Book Listed ,Federal Trade ,Live Webcast Today ,Orthostatic Hypotension Symptom Assessment ,Orthostatic Hypotension Daily Activity Scale ,Multiple System Atrophy ,Symptomatic Neurogenic Orthostatic Hypotension ,Private Securities Litigation Reform Act ,Securities Exchange Act ,Net Sales ,Neurological Disorders ,Annual Report ,Months Ended September ,While Viatris ,Markets ,